Clinical Trial Update: Raptiva in Palm and Sole Psoriasis [Phase 4]

View source ↗

Summary

Phase 4 study of Raptiva (efalizumab) for palm and sole involvement in chronic plaque psoriasis was terminated, with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Palmoplantar Psoriasis
• Plaque Psoriasis

Drugs mentioned

• Raptiva (efalizumab)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Chronic Plaque Psoriasis | Phase 4 | Status: TERMINATED | Results posted: 2010-09-02